Yesterday, Dec. 1, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.28 to $16,663,500.00.

Highlighted Stocks Traded by Insiders:

Becton Dickinson (BDX) - FREE Research Report

Gallagher John E, who is VP, Corp Finance and Treasurer at Becton Dickinson, sold 1,600 shares at $150.70 on Dec. 1, 2015. Following this transaction, the VP, Corp Finance and Treasurer owned 3,393 shares meaning that the stake was reduced by 32.04% with the 1,600-share transaction.

The shares most recently traded at $152.36, up $1.66, or 1.09% since the insider transaction. Historical insider transactions for Becton Dickinson go as follows:

  • 4-Week # shares sold: 3,659
  • 12-Week # shares sold: 3,659
  • 24-Week # shares sold: 3,659

The average volume for Becton Dickinson has been 992,300 shares per day over the past 30 days. Becton Dickinson has a market cap of $31.9 billion and is part of the health care sector and health services industry. Shares are up 9.71% year-to-date as of the close of trading on Tuesday.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The stock currently has a dividend yield of 1.76%. The company has a P/E ratio of 44.9. Currently, there are 10 analysts who rate Becton Dickinson a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDX - FREE

TheStreet Quant Ratings rates Becton Dickinson as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Becton Dickinson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celsion (CLSN) - FREE Research Report

EGWU, Inc. fka EGEN, Inc., who is 10% Owner at Celsion, sold 20,000 shares at $2.15 on Dec. 1, 2015. Following this transaction, the 10% Owner owned 2.4 million shares meaning that the stake was reduced by 0.81% with the 20,000-share transaction.

The shares most recently traded at $2.10, down $0.05, or 2.5% since the insider transaction. Historical insider transactions for Celsion go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 50,000

The average volume for Celsion has been 164,900 shares per day over the past 30 days. Celsion has a market cap of $47.4 million and is part of the health care sector and drugs industry. Shares are down 6.01% year-to-date as of the close of trading on Tuesday.

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. Currently, there are 4 analysts who rate Celsion a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLSN - FREE

TheStreet Quant Ratings rates Celsion as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Celsion Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Acacia Research (ACTG) - FREE Research Report

Harris Robert L Ii, who is Executive Chairman at Acacia Research, bought 15,000 shares at $5.71 on Dec. 1, 2015. Following this transaction, the Executive Chairman owned 354,808 shares meaning that the stake was boosted by 4.41% with the 15,000-share transaction.

The shares most recently traded at $5.90, up $0.19, or 3.22% since the insider transaction. Historical insider transactions for Acacia Research go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 34,273
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 34,273
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 34,273

The average volume for Acacia Research has been 552,400 shares per day over the past 30 days. Acacia Research has a market cap of $288.7 million and is part of the services sector and diversified services industry. Shares are down 64.7% year-to-date as of the close of trading on Tuesday.

Acacia Research Corporation, through its subsidiaries, invests in, develops, licenses, and enforces patented technologies in the United States. The stock currently has a dividend yield of 8.46%. Currently, there are 2 analysts who rate Acacia Research a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACTG - FREE

TheStreet Quant Ratings rates Acacia Research as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Acacia Research Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research